-Anas Younes Researcher Activity Profile

Research Author Detailed Information 

Anas Younes Publication Rate By Year

Anas Younes has published 1 paper(s) in 2005, 1 paper(s) in 2006, 3 paper(s) in 2007, 8 paper(s) in 2008, for a total of 13 research publications in total.

Anas A Younes Author Information

LAST NAME: younes

FIRST NAME: anas

INITIALS: A

AFFILIATION:

Papers

Anas Younes's Publication Record

1. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Year Published: 2006
Departments of Lymphoma and Myeloma, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
2. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Year Published: 2007
Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
3. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products. Year Published: 2007
Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.
4. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Year Published: 2005
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
5. Novel small-molecule therapy of Hodgkin lymphoma. Year Published: 2007
Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX 77030, USA. dbuglio@mdanderson.org
6. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Year Published: 2008
M.D., The U.T. M.D. Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA. panderli@mdanderson.org.
7. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Year Published: 2008
The U.T. M.D. Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA. panderli@mdanderson.org
8. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Year Published: 2008
Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
9. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Year Published: 2008
10. Nodular lymphocyte predominant Hodgkin's lymphoma. Year Published: 2008
University of Texas M.D. Anderson Cancer Center, Houston, USA.
11. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Year Published: 2008
Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA. nbartlet@wustl.edu
12. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma. Year Published: 2008
Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
13. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Year Published: 2008
The U.T. M.D. Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA. panderli@mdanderson.org